Table 2.
Key parameters extracted from the eligible studies.
| First Author | Year | Diagnostic Criteria |
BIRADS-Score | Associated Lesions |
Reference Standard |
Total Cases | TP | FP | FN | TN | FNi | totali |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hrkac Pustahija | 2018 | Enhancement | 4,5 | no | HE | 125 | 48 | 23 | 0 | 54 | 0 | 17 |
| Eun NL | 2018 | Enhancement | 4,5 | no | HE | 108 | 37 | 8 | 4 | 59 | 0 | 10 |
| Shimauchi A | 2018 | Enhancement | 4 | no | HE | 32 | 15 | 5 | 3 | 9 | 0 | 3 |
| Baltzer P | 2018 | BI-RADS | 4,5 | no | HE + FU | 152 | 69 | 49 | 2 | 32 | 0 | 30 |
| Bennani-Baiti | 2017 | BI-RADS | 4,5 | no | HE + FU | 248 | 103 | 25 | 4 | 116 | 1 | 84 |
| Strobel K | 2015 | BI-RADS | 4,5 | no | HE/FU | 78 | 22 | 8 | 3 | 45 | NA | NA |
| Li E | 2014 | BI-RADS | 4,5 | yes | HE | 51 | 22 | 21 | 1 | 7 | NA | NA |
| Zhu J | 2007 | BI-RADS | 3–5 | no | HE | 52 | 23 | 2 | 3 | 24 | 1 | 9 |
| Bazzocchi M | 2006 | Enhancement | 4,5 | yes | HE | 112 | 69 | 12 | 6 | 25 | 2 | 42 |
| Kneeshaw PJ | 2006 | BI-RADS | 3–5 | NA | HE | 88 | 15 | 7 | 5 | 61 | 2 | 10 |
| Bluemke D | 2004 | BI-RADS | 3–5 | yes | HE + FU | 300 | 106 | 42 | 21 | 131 | NA | NA |
| Trecate G | 2002 | Enhancement | 4,5 | yes | HE | 28 | 15 | 5 | 0 | 8 | 0 | 7 |
| Nakahara H | 2001 | Enhancement | 4,5 | no | HE | 40 | 19 | 4 | 1 | 16 | 0 | 6 |
FU = follow up, Enhancement = presence of enhancement (positive if not absent or diffuse), FN = false negative result, FP = false positive result, HE = histopathologic examination, i: invasive cancer, NA = not available, TN = true negative result, TP = true positive result.